 This 2-arm study evaluated the efficacy and safety of 2 different treatment schedules of oral Xeloda with intravenous IV Eloxatin oxaliplatin and IV bevacizumab Avastin as a first-line treatment in patients with locally advanced or metastatic colorectal cancer. Patients were randomized to receive either: 1 Xeloda 850 mgm2 orally twice a day po bid on Days 1-14, oxaliplatin 130 mgm2 IV on Day 1, and Avastin 7.5 mgkg IV on Day 1 of each 3-week cycle; or 2 Xeloda 1500 mgm2 po bid on Days 1-7, oxaliplatin 85 mgm2 IV on Day 1 and Avastin 5 mgkg IV on Day 1 of each 2-week cycle. The anticipated time on study treatment was 1-2 years, and the target sample size was 100-500 individuals. 